三友医疗：控股子公司产品通过创新医疗器械特别审查程序

Core Viewpoint - The announcement highlights that the company's subsidiary, Suzhou Yunhejing, has received special review approval from the National Medical Products Administration for its "Surface Porous Polyether Ether Ketone Interbody Fusion Device," which is the only device that meets the criteria of clear imaging, mechanical compatibility, and efficient bone integration. This product is expected to reach a global market size of $3.65 billion by 2032 [1]. Summary by Relevant Categories Product Development - The "Surface Porous Polyether Ether Ketone Interbody Fusion Device" is the only device that simultaneously satisfies clear imaging, mechanical compatibility, and efficient bone integration [1]. - The product's entry into the special review process will shorten the registration cycle and accelerate the time to market [1]. Market Potential - The global market size for this product is projected to reach $3.65 billion by 2032 [1]. - The approval and subsequent market entry are expected to enrich the company's product pipeline and positively impact its business [1].